Intervention

Nab paclitaxel

ClinicalTrials.gov intervention label

Clinical trials40
Recruiting12
Common conditions25
Lead sponsors shown15

Clinical trials

40 shown
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerNCT07340398 · 2025-12-25
RECRUITING
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerNCT07057427 · 2025-06-24
RECRUITING
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCNCT06786026 · 2024-10-09
RECRUITING
A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNCT06561685 · 2024-09-19
RECRUITING
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerNCT06387628 · 2024-07-10
RECRUITING
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.NCT06421298 · 2024-05-17
RECRUITING
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLCNCT05800340 · 2023-04-04
RECRUITING
Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerNCT05800587 · 2023-02-22
RECRUITING
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01
RECRUITING
A Study for the Adjuvant Treatment of Breast CancerNCT05420467 · 2022-07-10
RECRUITING
A Study for the Neoadjuvant Treatment of Breast CancerNCT05420454 · 2022-07-10
RECRUITING
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyNCT04253964 · 2020-07-01
RECRUITING
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBCNCT06632405 · 2025-04-01
NOT_YET_RECRUITING
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsNCT06607185 · 2024-10-21
ACTIVE_NOT_RECRUITING
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLCNCT06300424 · 2024-04-01
ACTIVE_NOT_RECRUITING
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNCT05116462 · 2024-03-15
ACTIVE_NOT_RECRUITING
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung AdenocarcinomaNCT05689671 · 2023-12-06
ACTIVE_NOT_RECRUITING
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerNCT05635708 · 2023-03-07
ACTIVE_NOT_RECRUITING
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung CancerNCT05493501 · 2022-12-14
TERMINATED
A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal AdenocarcinomaNCT05494866 · 2022-12-07
TERMINATED
Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02NCT05205200 · 2022-06-06
UNKNOWN
Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLCNCT05244213 · 2022-06-04
UNKNOWN
Pembro+Chemo in Brain MetsNCT04964960 · 2022-05-19
TERMINATED
Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast CancerNCT05251766 · 2022-04-20
UNKNOWN
A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerNCT05227664 · 2022-03-23
ACTIVE_NOT_RECRUITING
POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast CancerNCT04826016 · 2022-03-16
WITHDRAWN
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerNCT05014815 · 2021-11-16
COMPLETED
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCNCT04877821 · 2021-09-15
COMPLETED
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast CancerNCT04872985 · 2021-04-20
ACTIVE_NOT_RECRUITING
Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast CancerNCT04745975 · 2021-02-01
UNKNOWN
Precise Therapy for Refractory HER2 Positive Advanced Breast CancerNCT05429684 · 2021-01-01
UNKNOWN
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast CancerNCT04498793 · 2020-09-01
UNKNOWN
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLCNCT04405674 · 2020-07-15
UNKNOWN
Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)NCT04676997 · 2020-05-20
UNKNOWN
Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerNCT04355858 · 2020-05-01
UNKNOWN
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerNCT03554044 · 2020-02-05
COMPLETED
Study of DF1001 in Patients With Advanced Solid TumorsNCT04143711 · 2019-11-11
COMPLETED
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsNCT04083599 · 2019-09-17
ACTIVE_NOT_RECRUITING
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 · 2019-05-07
TERMINATED
Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsNCT03138889 · 2017-06-09
TERMINATED

Common conditions

Breast Cancer9Non-small Cell Lung Cancer8Lung Cancer3Non Small Cell Lung Cancer3Triple Negative Breast Cancer3Advanced Solid Tumor2HER2-negative Breast Cancer2Metastatic Cancer2Metastatic Solid Tumor2Advanced Breast Cancer1Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma1Anatomic Stage III Breast Cancer AJCC v81Anatomic Stage IIIA Breast Cancer AJCC v81Anatomic Stage IIIB Breast Cancer AJCC v81Anatomic Stage IIIC Breast Cancer AJCC v81Anatomic Stage IV Breast Cancer AJCC v81BRAF V600 Mutation1Brain Cancer1Breast Neoplasm1Breast Tumors1Cancer1Chemotherapy Effect1Colorectal Cancer1Colorectal Cancer (CRC)1CYP3A Inhibitor1

Trial status mix

RECRUITING12
UNKNOWN9
ACTIVE_NOT_RECRUITING8
TERMINATED5
COMPLETED4
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

PHASE228
PHASE19
PHASE34
PHASE43

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.